Literature DB >> 24573658

Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects.

Federico Nemmi1, Laure Saint-Aubert, Djilali Adel, Anne-Sophie Salabert, Jérémie Pariente, Emmanuel J Barbeau, Pierre Payoux, Patrice Péran.   

Abstract

PURPOSE: AV-45 amyloid biomarker is known to show uptake in white matter in patients with Alzheimer's disease (AD), but also in the healthy population. This binding, thought to be of a non-specific lipophilic nature, has not yet been investigated. The aim of this study was to determine the differential pattern of AV-45 binding in white matter in healthy and pathological populations.
METHODS: We recruited 24 patients presenting with AD at an early stage and 17 matched, healthy subjects. We used an optimized positron emission tomography-magnetic resonance imaging (PET-MRI) registration method and an approach based on an intensity histogram using several indices. We compared the results of the intensity histogram analyses with a more canonical approach based on target-to-cerebellum Standard Uptake Value (SUVr) in white and grey matter using MANOVA and discriminant analyses. A cluster analysis on white and grey matter histograms was also performed.
RESULTS: White matter histogram analysis revealed significant differences between AD and healthy subjects, which were not revealed by SUVr analysis. However, white matter histograms were not decisive to discriminate groups, and indices based on grey matter only showed better discriminative power than SUVr. The cluster analysis divided our sample into two clusters, showing different uptakes in grey, but also in white matter.
CONCLUSION: These results demonstrate that AV-45 binding in white matter conveys subtle information not detectable using the SUVr approach. Although it is not more efficient than standard SUVr in discriminating AD patients from healthy subjects, this information could reveal white matter modifications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573658      PMCID: PMC5101350          DOI: 10.1007/s00259-014-2728-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

2.  Regional white matter hyperintensities in normal aging, single domain amnestic mild cognitive impairment, and mild Alzheimer's disease.

Authors:  Jung Hwa Kim; Kyoung Jin Hwang; Jun-Hyun Kim; Young Ha Lee; Hak Young Rhee; Key-Chung Park
Journal:  J Clin Neurosci       Date:  2011-07-02       Impact factor: 1.961

3.  The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers.

Authors:  David Wallon; Stéphane Rousseau; Anne Rovelet-Lecrux; Muriel Quillard-Muraine; Lucie Guyant-Maréchal; Olivier Martinaud; Jérémie Pariente; Michèle Puel; Adeline Rollin-Sillaire; Florence Pasquier; Isabelle Le Ber; Marie Sarazin; Bernard Croisile; Claire Boutoleau-Bretonnière; Catherine Thomas-Antérion; Claire Paquet; Olivier Moreaud; Audrey Gabelle; François Sellal; Mathilde Sauvée; Annie Laquerrière; Charles Duyckaerts; Marie-Bernadette Delisle; Nathalie Streichenberger; Béatrice Lannes; Thierry Frebourg; Didier Hannequin; Dominique Campion
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

5.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Authors:  Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-08       Impact factor: 9.236

6.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

7.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

8.  Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

Authors:  Renaud La Joie; Audrey Perrotin; Louisa Barré; Caroline Hommet; Florence Mézenge; Méziane Ibazizene; Vincent Camus; Ahmed Abbas; Brigitte Landeau; Denis Guilloteau; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion.

Authors:  Eric Westman; J-Sebastian Muehlboeck; Andrew Simmons
Journal:  Neuroimage       Date:  2012-05-03       Impact factor: 6.556

10.  Classification of structural MRI images in Alzheimer's disease from the perspective of ill-posed problems.

Authors:  Ramon Casanova; Fang-Chi Hsu; Mark A Espeland
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more
  9 in total

1.  Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.

Authors:  P Payoux; J Delrieu; A Gallini; D Adel; A S Salabert; A Hitzel; C Cantet; M Tafani; D De Verbizier; J Darcourt; Ph Fernandez; J Monteil; I Carrié; T Voisin; S Gillette-Guyonnet; M Pontecorvo; B Vellas; S Andrieu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-08       Impact factor: 9.236

2.  Yes we can analyse amyloid images - Now What?

Authors:  Henryk Barthel; John Seibyl; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05       Impact factor: 9.236

3.  Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden.

Authors:  Janusch Blautzik; Matthias Brendel; Julia Sauerbeck; Sebastian Kotz; Franziska Scheiwein; Peter Bartenstein; John Seibyl; Axel Rominger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

4.  Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice.

Authors:  Andrew T Templin; Daniel T Meier; Joshua R Willard; Tami Wolden-Hanson; Kelly Conway; Yin-Guo Lin; Patrick J Gillespie; Krister B Bokvist; Giorgio Attardo; Steven E Kahn; Donalyn Scheuner; Rebecca L Hull
Journal:  Diabetologia       Date:  2018-07-25       Impact factor: 10.122

5.  Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease.

Authors:  Ya-Ting Chang; Chi-Wei Huang; Nai-Ching Chen; Kun-Ju Lin; Shu-Hua Huang; Yen-Hsiang Chang; Shih-Wei Hsu; Wen-Neng Chang; Chun-Chung Lui; Che-Wei Hsu; Chiung-Chih Chang
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

6.  Spill-in counts in the quantification of 18F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region.

Authors:  Francisco Javier López-González; Alexis Moscoso; Nikos Efthimiou; Anxo Fernández-Ferreiro; Manuel Piñeiro-Fiel; Stephen J Archibald; Pablo Aguiar; Jesús Silva-Rodríguez
Journal:  EJNMMI Phys       Date:  2019-12-19

7.  Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment.

Authors:  Santiago Bullich; John Seibyl; Ana M Catafau; Aleksandar Jovalekic; Norman Koglin; Henryk Barthel; Osama Sabri; Susan De Santi
Journal:  Neuroimage Clin       Date:  2017-05-13       Impact factor: 4.881

8.  Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury.

Authors:  Abdalla Z Mohamed; Paul Cumming; Hussein Srour; Tamara Gunasena; Aya Uchida; Courtney Nicole Haller; Fatima Nasrallah
Journal:  Neuroimage Clin       Date:  2018-06-05       Impact factor: 4.881

9.  Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study).

Authors:  Antoine Yrondi; Bruno Aouizerate; Wissam El-Hage; Fanny Moliere; Claire Thalamas; Nicolas Delcourt; Marie Sporer; Simon Taib; Laurent Schmitt; Nicolas Arlicot; Deborah Meligne; Agnes Sommet; Anne S Salabert; Sebastien Guillaume; Philippe Courtet; Florence Galtier; Denis Mariano-Goulart; Nicolas Menjot De Champfleur; Emmanuelle Le Bars; Thomas Desmidt; Mathieu Lemaire; Vincent Camus; Maria J Santiago-Ribeiro; Jean P Cottier; Philippe Fernandez; Marie Meyer; Vincent Dousset; Olivier Doumy; Didier Delhaye; Lucile Capuron; Marion Leboyer; Emmanuel Haffen; Patrice Péran; Pierre Payoux; Christophe Arbus
Journal:  Front Psychiatry       Date:  2018-07-24       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.